4 Analysts Assess Denali Therapeutics: What You Need To Know

In the last three months, 4 analysts have published ratings on Denali Therapeutics DNLI, offering a diverse range of perspectives from bullish to bearish.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $65.75, with a high estimate of $105.00 and a low estimate of $31.00. This current average has decreased by 37.38% from the previous average price target of $105.00.

Decoding Analyst Ratings: A Detailed Look

The standing of Denali Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Denali Therapeutics. This offers insight into analysts' perspectives on the current state of the company.
• Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Denali Therapeutics compared to the broader market.
• Price Targets: Analysts predict movements in price targets, offering estimates for Denali Therapeutics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Denali Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on Denali Therapeutics analyst ratings.

Unveiling the Story Behind Denali Therapeutics

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Key Indicators: Denali Therapeutics's Financial Health

Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.

Decline in Revenue: Over the 3 months period, Denali Therapeutics faced challenges, resulting in a decline of approximately -64.4% in revenue growth as of 30 September, 2023. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Denali Therapeutics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -7841.59%, the company may face hurdles in effective cost management.

Return on Equity (ROE): Denali Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -8.62%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -7.82%, the company showcases effective utilization of assets.

Debt Management: Denali Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.05.

Analyst Ratings: Simplified

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga's automated content engine and reviewed by an editor.